Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

PURPOSE: Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib. Regorafenib is a structurally unique inhibitor of multiple cancer-associated kinases, including KIT and platelet-derived growth factor receptor (PDGFR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: George, Suzanne, Wang, Qian, Heinrich, Michael C., Corless, Christopher L., Zhu, Meijun, Butrynski, James E., Morgan, Jeffrey A., Wagner, Andrew J., Choy, Edwin, Tap, William D., Yap, Jeffrey T., Van den Abbeele, Annick D., Manola, Judith B., Solomon, Sarah M., Fletcher, Jonathan A., von Mehren, Margaret, Demetri, George D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675695/
https://ncbi.nlm.nih.gov/pubmed/22614970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.9394
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados